Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101.

@article{Frei2008AntitumourEI,
  title={Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101.},
  author={Gabi M Frei and Markus Kremer and K-M O Hanschmann and Sarah Krause and Michael Albeck and Benjamin Sredni and Barbara S. Schnierle},
  journal={The British journal of dermatology},
  year={2008},
  volume={158 3},
  pages={578-86}
}
BACKGROUND The immunomodulator AS101 [ammonium trichloro (dioxoethylene-O,O') tellurate], a nontoxic tellurium (IV) compound, has antitumoral effects which were demonstrated in several preclinical and clinical studies. OBJECTIVES To investigate the antitumour activity of AS101 on cutaneous T-cell lymphoma (CTCL), of which mycosis fungoides (MF) is the most frequent disease variant. METHODS We used a newly established mouse xenograft model for MF to test the effect of AS101 in vivo and… CONTINUE READING